Anastrozole and tamoxifen yield similar disease recurrence outcomes in postmenopausal women with ductal carcinoma in situ (DCIS), but side-effect profiles of the two vary, making anastrozole suitable for women with contraindications to tamoxifen, the phase III IBIS-II DCIS (International Breast Cancer Intervention-II DCIS) trial has shown.
Adjuvant capecitabine therapy significantly improved disease-free survival (DFS) in HER2-negative primary breast cancer patients with residual invasive disease after neoadjuvant chemotherapy (NAC), according to results of the CREATE-X* trial presented at the recent San Antonio Breast Cancer Symposium 2015 in San Antonio, Texas, US.
Adjuvant treatment with a low dose of denosumab decreased the risk of fractures and improved disease-free survival (DFS) in postmenopausal women with early, HR-positive breast cancer, when added to aromatase inhibitor (AI) therapy.
Treatment with eluxadoline, a new oral medication, relieved two major symptoms of irritable bowel syndrome with diarrhoea (IBS-D) — abdominal pain and diarrhoea, according to a study based on two phase III randomized controlled trials. [N Engl J Med 2016;374:242-253]
Taking oral antibiotics appears to increase the risk of nephrolithiasis, according to a recent study. Moreover, the risk seems to be compounded for individuals with recent antibiotic exposure and those who were exposed at a younger age.
Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.